BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Odhiambo R, Chhatwal J, Ferrante SA, El Khoury A, Elbasha E. Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary. JHEOR 2013;1:62-82. [DOI: 10.36469/9854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 San Miguel R, Gimeno-ballester V, Mar J. Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Review of Pharmacoeconomics & Outcomes Research 2014;14:387-402. [DOI: 10.1586/14737167.2014.906307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
2 Chhatwal J, He T, Hur C, Lopez-Olivo MA. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. Clin Gastroenterol Hepatol. 2017;15:827-837.e8. [PMID: 27650326 DOI: 10.1016/j.cgh.2016.09.015] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 10.5] [Reference Citation Analysis]